Bitcoin price today: rises above $111k amid easing trade jitters; US CPI on tap
Investing.com -- Inhibrx Biosciences (NASDAQ:INBX) stock surged 70% after reporting positive topline results from its registrational trial of ozekibart in chondrosarcoma, a rare type of bone cancer.
The company announced that the ChonDRAgon study met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival compared to placebo. Ozekibart achieved a 52% reduction in the risk of disease progression or death versus placebo, with consistent benefits across all pre-specified subgroups.
Key secondary endpoints further supported the drug’s efficacy, with ozekibart showing a disease control rate of 54% compared to 27.5% for placebo. The treatment also delayed deterioration in pain and physical function, providing meaningful improvements in patient quality of life.
The drug was generally well tolerated with a manageable safety profile. Common treatment-related adverse events included fatigue, constipation, and nausea. While hepatotoxicity was noted as a risk, the company implemented mitigation measures that reduced the incidence of liver-related events.
Inhibrx also reported promising interim data from expansion cohorts in colorectal cancer and Ewing sarcoma. In heavily pretreated colorectal cancer patients, ozekibart in combination with FOLFIRI demonstrated a 23% overall response rate and 92% disease control rate. For Ewing sarcoma, the combination of ozekibart with irinotecan and temozolomide showed a 64% overall response rate and 92% disease control rate.
The company plans to file a Biologics License Application (BLA) for ozekibart in the second quarter of 2026. Detailed results from the chondrosarcoma trial will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.